Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment
EFS benefit is seen with sasanlimab in CIS and T1 NMIBC
Perioperative sacituzumab govitecan/pembro yields compelling CR rate in MIBC
Interim ENLIGHTED data show promise for padeliporfin VTP therapy in UTUC
